Navigation Links
Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma
Date:11/9/2008

SEATTLE, Nov. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has published in the November 1, 2008 issue the results of a study authored by Samual Jacobs et al. investigating the use of short-course CHOP-R followed by Zevalin ([90Y]-ibritumomab tiuxetan) and extended rituximab as first-line treatment in follicular non-Hodgkin's lymphoma patients. Addition of the Zevalin therapeutic regimen increased the complete responses from 40% for patients evaluated after 3 cycles of CHOP-R alone to 82% after the Zevalin regimen.

"This study adds to recently published First-line Indolent Trial (FIT) data indicating that the addition of Zevalin in patients who respond to first-line treatment of follicular non-Hodgkin's lymphoma patients may enhance the depth of response, even in patients whose induction therapy included rituximab-containing regimens," noted Jack Singer, M.D., Chief Medical Officer at Cell Therapeutics.

This trial enrolled 60 patients of which 55 patients completed all protocol therapy. Patients who had received no prior therapy with chemotherapy or monoclonal antibody received standard dose CHOP-R for 3 cycles followed by Zevalin then were treated with rituximab weekly for 4 doses. CHOP-R related toxicities included grade 3 to 4 neutropenia occurred in 23 (39%) patients and grade 3 to 4 thrombocytopenia occurred in 3 (5%) patients. The most frequent toxicity associated with Zevalin was myelosuppression. Grade 3 to 4 neutropenia occurred in 28 (51%) of patients with one incidence of febrile neutropenia requiring hospitalization. Grade 3 to 4 thrombocytopenia occurred in 44% of patients. However, all 55 patients who received Zevalin had normal white blood counts and platelet counts by after 12 weeks following administration.

Zevalin is currently approved in the United States for the treatment of patients with relapsed or refractory, low-grade or follicular B
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
2. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
3. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
4. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
7. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
8. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
9. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
10. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
11. New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- CipherHealth, a leading provider of innovations and solutions designed ... to the Nepalese American Nursing Association to donate money ... Nepal to aid in disaster ... addition to helping fund the travel costs for the ... medical supplies for the mission.  "Our ...
(Date:5/5/2015)... , May 5, 2015 Zimmer Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2015. The cash dividend of ... 14, 2015, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:5/5/2015)... 5, 2015 Silver Creek Pharmaceuticals, Inc. announced ... (SBIR) grant from the National Institute of Health (NIH). ... San Francisco based biotechnology company that discovers ... damaged by disease. This award will be used to ... tissue following a heart attack. Silver Creek,s ...
Breaking Medicine Technology:Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2
... plc (LSE: SHP, NASDAQ: SHPGY ), the global ... rights to develop and market Resolor ® (prucalopride) in ... N.V.  Terms of the agreement have not been disclosed. ... portfolio in Europe and is approved for use in 33 ...
... BabyPing will unveil a new high ... - CES - this week. The new BabyPing high security ... their infant on iPhone, iPad or iPod Touch through cutting edge ... truly reassuring alternative to old-style monitors by using the latest in ...
Cached Medicine Technology:Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4BabyPing Wi-Fi Baby Monitor for iOS Debuts at CES - the Next Generation of Baby Monitor is Here 2
(Date:5/5/2015)... (PRWEB) May 05, 2015 Private equity ... FZ LLC has announced that its dental stem cell ... Store-A-Tooth™ increased once again--in April, 2015 –and posted yet ... of increased record volume and represents a significant 54% ... dental stem cell biobank is conducted via the Store-A-Tooth ...
(Date:5/5/2015)... Indian Trail, NC (PRWEB) May 05, 2015 ... firm serving Indian Trail, Monroe, Matthews, Charlotte and surrounding ... in the field of accounting. This company provides assistance ... a priority as they prepare individual or corporate tax ... a system in the cloud that allows clients (and ...
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... 05, 2015 Hiliary Critchley, Senior ... present at the 24th Annual WEDI National ... MT in Scottsdale, AZ. WEDI, the Workgroup for ... authority on the use of health IT to ... National Director of Telemedicine for UnitedHealthcare will co-present ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... ) filed on behalf of men who ... their use of prescription testosterone replacement therapies ... multidistrict litigation underway in U.S. District Court, ... documents dated May 1st, defendants AbbVie, Inc., ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4
... ... Provider Earns $1.6 Million in Rebates This Year, Highlights ... Redwood City Project, REDWOOD ... nation,s largest not-for-profit,health plan, will today celebrate significant energy efficiency upgrades,and solar installations ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... announced today that it will present at the,18th ... York City. The,Company,s presentation is scheduled for Monday, ... Hinson, president and chief executive officer, will,review the ...
... method for evaluating the eyes ability to distinguish object ... (AMD) could provide a more accurate way to assess ... with devices and training, according to a Canadian study. ... high-contrast illumination targets for testing spatial vision, which the ...
... Mack, Inc., a leading provider,of case management software ... care organizations, announced the Columbiana County (Ohio) Board ... its Q,Continuum System. Q Continuum System, CH ... contains a complete suite of functions,supporting "best in ...
... Hovione,s Technology,Transfer Center (TTC) in New Jersey has ... inspection was carried out by Ms. Joy R. Kozlowski-Klena ... and Research (CDER) and,lasted 3 days, starting on October ... issued. At the closing meeting, the inspector had several ...
... Nears, NEW YORK, Oct. 29 - An overwhelming ... issue with their,doctors despite recent visits, and an alarming ... are risk factors for dementia, according to,results of a ... the Alzheimer,s Foundation of America (AFA)., These findings ...
Cached Medicine News:Health News:The Healing Power of Green 2Health News:The Healing Power of Green 3Health News:Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 2Health News:Test for visual acuity could aid detection, rehabilitation of AMD 2Health News:Columbiana County Board of MR/DD Chooses Q Continuum(TM) System 2Health News:Columbiana County Board of MR/DD Chooses Q Continuum(TM) System 3Health News:FDA Inspects Hovione's Technology Transfer Center in New Jersey 2Health News:Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns 2Health News:Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns 3Health News:Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns 4
Full plate covers seal all 24 MicroAmp tubes...
An alternative sealing method for samples that are stored in 96-well plates after PCR. The mat is fully autoclavable and can be reused up to 50 times....
Inquire...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Medicine Products: